SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...

Related Keywords

Heidelberg ,Baden Wüberg ,Germany ,United States ,Mannheim ,Samantha Hilson Sandler ,Saqib Islam ,Bernd Kasper ,Desmoid Tumor Working Group ,European Union ,Drug Administration ,Twitter ,European Commission ,European Society For Medical Oncology Congress ,Linkedin ,Youtube ,European Medicines Agency ,Springworks Therapeutics Inc ,Mannheim Cancer Center ,Nasdaq ,University Of Heidelberg ,Works Therapeutics ,Marketing Authorization Application ,Orphan Drug ,Chief Executive Officer ,New England Journal ,Presidential Symposium ,European Society ,Medical Oncology Congress ,Principal Investigator ,Important Safety ,Melanoma Skin Cancers ,Embryo Fetal Toxicity ,Acid Reducing Agents ,Prescribing Information ,Springworks Therapeutics ,Private Securities Litigation Reform Act ,Springwork Annual Report ,Gamma Secretase Inhibitor ,Dei Tos ,Soft Tissue Tumours ,Report Series ,Rare Diseases ,Tumor Working ,